557 related articles for article (PubMed ID: 28892469)
1. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.
Johansson-Percival A; He B; Li ZJ; Kjellén A; Russell K; Li J; Larma I; Ganss R
Nat Immunol; 2017 Nov; 18(11):1207-1217. PubMed ID: 28892469
[TBL] [Abstract][Full Text] [Related]
2. Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy.
He B; Johansson-Percival A; Backhouse J; Li J; Lee GYF; Hamzah J; Ganss R
Cell Rep; 2020 Jan; 30(3):714-724.e5. PubMed ID: 31968248
[TBL] [Abstract][Full Text] [Related]
3. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
Tang H; Wang Y; Chlewicki LK; Zhang Y; Guo J; Liang W; Wang J; Wang X; Fu YX
Cancer Cell; 2016 Mar; 29(3):285-296. PubMed ID: 26977880
[TBL] [Abstract][Full Text] [Related]
4. TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy.
Skeate JG; Otsmaa ME; Prins R; Fernandez DJ; Da Silva DM; Kast WM
Front Immunol; 2020; 11():922. PubMed ID: 32499782
[TBL] [Abstract][Full Text] [Related]
5. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.
Peske JD; Woods AB; Engelhard VH
Adv Cancer Res; 2015; 128():263-307. PubMed ID: 26216636
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
8. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
Fridman WH; Petitprez F; Sautes-Fridman C
Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
[No Abstract] [Full Text] [Related]
9. T cell exclusion, immune privilege, and the tumor microenvironment.
Joyce JA; Fearon DT
Science; 2015 Apr; 348(6230):74-80. PubMed ID: 25838376
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function.
Beyranvand Nejad E; Labrie C; van der Sluis TC; van Duikeren S; Franken KLMC; Roosenhoff R; Arens R; van Hall T; van der Burg SH
Int J Cancer; 2021 Jan; 148(1):211-225. PubMed ID: 32875568
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy.
Schmittnaegel M; De Palma M
Trends Cancer; 2017 Dec; 3(12):809-812. PubMed ID: 29198436
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.
Fabian KL; Storkus WJ
Adv Exp Med Biol; 2017; 1036():191-211. PubMed ID: 29275473
[TBL] [Abstract][Full Text] [Related]
14. Repurposing infectious disease vaccines for intratumoral immunotherapy.
Melero I; Gato M; Shekarian T; Aznar A; Valsesia-Wittmann S; Caux C; Etxeberrria I; Teijeira A; Marabelle A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32102830
[TBL] [Abstract][Full Text] [Related]
15. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.
He B; Jabouille A; Steri V; Johansson-Percival A; Michael IP; Kotamraju VR; Junckerstorff R; Nowak AK; Hamzah J; Lee G; Bergers G; Ganss R
J Pathol; 2018 Jun; 245(2):209-221. PubMed ID: 29603739
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in lymphoma.
Ansell SM; Caligaris-Cappio F; Maloney DG
Hematol Oncol; 2017 Jun; 35 Suppl 1():88-91. PubMed ID: 28591421
[No Abstract] [Full Text] [Related]
17. Relieving immunosuppression by Endo@PLT targeting anti-angiogenesis to improve the efficacy of immunotherapies.
Chen C; Tang Y; Huang H; Jia L; Feng L; Zhao J; Zhang H; He J; Ding L; Xia D
Chem Commun (Camb); 2022 Mar; 58(19):3202-3205. PubMed ID: 35174839
[TBL] [Abstract][Full Text] [Related]
18. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.
Schaaf MB; Garg AD; Agostinis P
Cell Death Dis; 2018 Jan; 9(2):115. PubMed ID: 29371595
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
[TBL] [Abstract][Full Text] [Related]
20. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Trujillo JA; Sweis RF; Bao R; Luke JJ
Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
